Polycystic Kidney Disease | Treatment Algorithms: Claims Data Analysis | US | 2024

Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease (PKD), is a genetic disorder in which fluid-filled cysts progressively develop in the kidney, leading to kidney damage and failure. Current treatments focus primarily on managing hypertension, the most common symptom of ADPKD. RAAS inhibitors, particularly lisinopril, dominate first-line therapy, and beta blockers, calcium channel blockers (CCBs), and diuretics compete for patient share in second-line therapy. Jynarque (tolvaptan) is the only disease-modifying therapy approved for ADPKD; it is used as first-line treatment in patients with rapidly progressing disease. This longitudinal analysis of claims data provides detailed insight into U.S. prescribing patterns for ADPKD.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed ADPKD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed ADPKD patients?
• How has Otsuka’s Jynarque (tolvaptan) been integrated into the treatment algorithm, and what is its source of business?
• What percentage of ADPKD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of ADPKD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Markets covered: United States

Key companies: Otsuka, Pfizer, Bausch Health, Merck, Novartis, GlaxoSmithKline

Key drugs: Jynarque (tolvaptan), ACE inhibitors, ARBs, CCBs, diuretics, beta blockers

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses